ClinicalTrials.gg
CompletedNCT02949011CAPSTONE 2Updated Nov 19, 2019Results posted

Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications

A Phase 3 interventional study of Baloxavir Marboxil and Placebo to Baloxavir Marboxil in Influenza, sponsored by Shionogi. Completed. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2019-11-19.

Sponsored by Shionogi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,184
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing baloxavir in Influenza, Human — 7 open to participants now, 7 under way, 5 of them phase 3. baloxavir · Influenza, Human.

Enrollment
4th of 18
2,184 · median 483
Started
2017
the only one that year
Phase 3
12 of 18
5 open now
Registered
2nd of 18
by date
Lead sponsor
2 of 18
Shionogi

Among the 18 studies testing baloxavir in Influenza, Human, this one is the 4th largest by enrollment, is the only one that started in 2017, is one of 12 in phase 3, and was the 2nd registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

7 of the 18 studies testing baloxavir in Influenza, Human are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About baloxavir

baloxavir: first FDA approval 2018 (XOFLUZA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing baloxavir in Influenza, Human, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo by measuring the time to improvement of influenza symptoms in patients with influenza presenting within 48 hours of symptom onset.

03

Conditions studied

  • Influenza

Browse trials for

Keywords

  • Tamiflu®
  • Influenza
  • Oseltamivir
  • Flu
  • S-033188
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients or their legal guardians who provide written to participate in the study on a voluntary basis. For adolescent patients, informed consent/assent of voluntary participation should be obtained in accordance with local requirements.
  2. Male or female patients ≥ 12 years at the time of signing the informed consent/assent form.
  3. Patients with a diagnosis of influenza confirmed by all of the following:

    1. Fever ≥ 38ºC (axillary) during the predose examinations or within the 4 hours prior if antipyretics were taken
    2. A positive rapid influenza diagnostic test (RIDT) result OR A patient with a negative RIDT may be enrolled if the patient reports contact with a known case of influenza within the prior 7 days and all other inclusion criteria are met.
    3. At least 1 each of the following general and respiratory symptoms associated with influenza is present with a severity of moderate or greater:

    i. General symptoms (headache, feverishness or chills, muscle or joint pain, or fatigue) ii. Respiratory symptoms (cough, sore throat, or nasal congestion)

  4. The time interval between the onset of symptoms and the predose examinations is 48 hours or less. The onset of symptoms is defined as either:

    1. Time of the first increase in body temperature (an increase of at least 1ºC from normal body temperature)
    2. Time when the patient experiences at least 1 new general or respiratory symptom
  5. If a women of , agrees to use a highly effective method of for 3 months after the first dose of study drug
  6. Patients will be considered at high risk* of influenza complications due to the presence of at least 1 of the following inclusion criteria:

    1. Asthma or chronic lung disease (such as or cystic fibrosis)
    2. Endocrine disorders (including diabetes mellitus)
    3. Residents of long-term care facilities (eg, nursing homes)
    4. Compromised immune system (including patients receiving not exceeding 20 mg of prednisolone or equivalent, and patients being treated for [HIV] infection with a > 350 cells/mm³ within the last 6 months)
    5. Neurological and neurodevelopmental disorders (including disorders of the brain, spinal cord, peripheral nerve, and muscle, eg, cerebral palsy, epilepsy [seizure disorders], stroke, muscular dystrophy, or spinal cord injury)
    6. Heart disease (such as congenital heart disease, congestive heart failure, or coronary artery disease), excluding hypertension without any other heart-related symptoms
    7. Adults aged ≥ 65 years
    8. American Indians and Alaskan Natives
    9. Blood disorders (such as sickle cell disease)
    10. Metabolic disorders (such as inherited metabolic disorders and mitochondrial disorders)
    11. Morbid obesity ( ≥ 40 kg/m²)
    12. Women who are within 2 weeks postpartum and are not breastfeeding

Exclusion criteria

Exclusion Criteria:

  1. Patients with severe influenza virus infection requiring inpatient treatment.
  2. Patients with known allergy to oseltamivir (Tamiflu®).
  3. Patients unable to swallow tablets or capsules.
  4. Patients who have previously received baloxavir marboxil.
  5. Patients weighing ≤ 40 kg.
  6. Patients who have been exposed to an drug within 30 days prior to the predose examinations.
  7. Women who are pregnant, breastfeeding, or have a positive pregnancy test at the predose examinations. The following female patients who have documentation of either a or b below do not need to undergo a pregnancy test at the predose examinations:

    1. women (defined as cessation of regular menstrual periods for 2 years or more and confirmed by a follicle-stimulating hormone test)
    2. Women who are surgically sterile by hysterectomy, bilateral oophorectomy, or tubal ligation
  8. Patients with concurrent infections at the predose examinations requiring systemic antimicrobial therapy.
  9. Patients with liver disease associated with hepatic impairment.
  10. Patients with cancer within the last 5 years (unless nonmelanoma skin cancer).
  11. Patients with untreated infection or treated HIV infection with a below 350 cells/mm3 in the last 6 months.
  12. Patients with following organ or bone marrow transplants.
  13. Patients exceeding 20 mg of prednisolone or equivalent dose of chronic systemic .
  14. Patients who have received peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir or amantadine within 30 days prior to the predose examinations.
  15. Patients who have received an investigational monoclonal antibody for a viral disease in the last year.
  16. Patients with known ≤ 60 mL/min.
  17. Patients who, in the opinion of the investigator, would be unlikely to comply with required study visits, self-assessments, and interventions
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
2,184 participants (actual)

Study arms

  • Experimental
    Baloxavir Marboxil

    Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of \< 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.

    Drug: Baloxavir Marboxil · Drug: Placebo to Oseltamivir

  • Active comparator
    Oseltamivir

    Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.

    Drug: Placebo to Baloxavir Marboxil · Drug: Oseltamivir

  • Placebo comparator
    Placebo

    Participants received placebo to baloxavir marboxil on Day 1 and placebo to oseltamivir orally twice a day on Days 1 to 5.

    Drug: Placebo to Baloxavir Marboxil · Drug: Placebo to Oseltamivir

Interventions

  • Tablets taken orally

    Also known as: S-033188, Xofluza®

  • DrugPlacebo to Baloxavir Marboxil

    Matching tablets taken orally

  • Capsules taken orally

    Also known as: Tamiflu®

  • DrugPlacebo to Oseltamivir

    Matching placebo capsules taken orally

06

What researchers measure

Primary outcomes

  1. Time to Improvement of Influenza Symptoms

    Participants assessed the severity of 7 influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness/chills, muscle/joint pain, and fatigue) on a 4-point scale (0 = no symptoms, 1= mild, 2 = moderate, and 3 = severe). Time to improvement of symptoms was defined as the time from the start of treatment to the time when all influenza symptoms were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours: * Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline * Preexisting symptoms not worse at baseline must have maintained baseline severity * New symptoms must have alleviated, defined as a symptom score of none (0) or mild (1). Time to improvement of symptoms was analyzed using Kaplan-Meier (KM) methods; participants who did not experience improvement of symptom s were censored at the last observation.

    Time frame: From Day 1 pretreatment up to Day 14

Secondary outcomes

  1. Percentage of Participants With Positive Influenza Virus Titer at Each Time Point

    Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) using tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log₁₀ of the 50% tissue culture infective dose (TCID₅₀/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6, and 9.

    Time frame: Days 2, 3, 4 (optional), 5, 6 (optional), and 9

  2. Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point

    Influenza virus ribonucleic acid (RNA) was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log₁₀ virus particles/mL) measured by reverse transcription polymerase chain reaction (RT-PCR) among those assessed on Days 2, 3, 4, 5, 6 and 9.

    Time frame: Days 2, 3, 4 (optional), 5, 6 (optional), and 9.

  3. Change From Baseline in Virus Titer at Each Time Point

    Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID₅₀/mL).

    Time frame: Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9

  4. Change From Baseline in Virus RNA (RT-PCR) at Each Time Point

    Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA was measured by reverse transcription polymerase chain reaction (RT-PCR).

    Time frame: Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9

  5. Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer

    This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.

    Time frame: Day 1 to Day 9

  6. Area Under the Curve (AUC) Adjusted by Baseline in Viral RNA

    This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.

    Time frame: Day 1 to Day 9

  7. Time to Cessation of Viral Shedding Determined by Virus Titer

    Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log₁₀\[TCID₅₀/mL\]). The median and 95% confidence interval (CI) for time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.

    Time frame: Day 1 to Day 9

  8. Time to Cessation of Viral Shedding Determined by Virus RNA

    Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR. Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.

    Time frame: Day 1 to Day 9

  9. Percentage of Participants Whose Symptoms Were Improved at Each Time Point

    Participants assessed the severity of 7 influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (0 = no symptoms, 1= mild, 2 = moderate, and 3 = severe). Improvement of symptoms was defined as all influenza symptoms alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours: * Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) judged to be worse at baseline must have improved at least 1 point from baseline severity * Preexisting symptoms judged not to be worse at baseline must have maintained baseline severity * New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1).

    Time frame: 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment

  10. Time to Alleviation of Symptoms

    Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of symptoms was analyzed using Kaplan-Meier (KM) methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.

    Time frame: Initiation of study treatment up to Day 14

  11. Time to Improvement of the Four Systemic Symptoms

    Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (from 0 = no symptoms to 3 = severe symptoms). Time to improvement of the 4 systemic symptoms was defined as the time between the initiation of study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours: * Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline * Preexisting symptoms not worse at baseline must have maintained baseline severity * New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1). Time to improvement of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience improvement of symptoms were censored at the last observation.

    Time frame: Initiation of study treatment up to Day 14

  12. Time to Improvement of the Three Respiratory Symptoms

    Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (from 0 = no symptoms to 3 = severe symptoms). Time to improvement of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat, and nasal congestion) were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours: * Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline * Preexisting symptoms not worse at baseline must have maintained baseline severity * New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1). Time to improvement of the 3 respiratory symptoms was analyzed using KM methods; participants who did not experience improvement of symptoms were censored at the last observation time point.

    Time frame: Initiation of study treatment up to Day 14

  13. Time to Resolution of Fever

    Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for at least 12 hours. Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.

    Time frame: Initiation of study treatment up to Day 14

  14. Percentage of Participants Reporting Normal Temperature at Each Time Point

    Defined as the percentage of patrticipants whose axillary body temperature dropped to less than 37ºC after the initiation of the study treatment.

    Time frame: 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment

  15. Body Temperature at Each Time Point

    Participant's self-measured axillary temperature using an electronic thermometer.

    Time frame: 12, 24, 36, 48, 72, 96 and 120 hours after the initial dose of study treatment

  16. Time to Improvement of Individual Symptoms

    Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (0 = no symptoms to 3 = severe). Time to improvement of cough, fatigue, and muscle/joint pain was defined as the time from the start of treatment to the time when each symptom was alleviated, maintained, or improved, as defined below, for at least 21.5 hours: * Preexisting symptoms that were worse at baseline must have improved at least 1 point from baseline * Preexisting symptoms not worse at baseline must have maintained baseline severity * New symptoms must have alleviated, defined as a score of 0 (None) or 1 (Mild). Time to improvement of sore throat, headache, nasal congestion, and feverish/chills was defined as the time from the start of treatment to the time when the symptom was assessed as 0 (None) or 1 (Mild) for at least 21.5 hours. Time to improvement of symptoms was analyzed using KM methods; participants with no improvement of symptoms were censored at the last observation.

    Time frame: Initiation of study treatment up to Day 14

  17. Time to Return to Preinfluenza Health Status

    Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health \[for someone your age and condition\]), and their health status at baseline and every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score. Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.

    Time frame: Baseline to Day 14

  18. Percentage of Participants Requiring Systemic Antibiotics for Infections Secondary to Influenza Infection

    The percentage of participants who received systemic antibiotics for any of the predefined complications (sinusitis, otitis media, bronchitis and pneumonia).

    Time frame: Day 2 to Day 22

  19. Percentage of Participants With Influenza-related Complications

    Defined as the percentage of patients who experience each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically-confirmed pneumonia) as an adverse event after the initiation of study treatment.

    Time frame: Day 1 to Day 22

  20. Percentage of Participants With Adverse Events (AEs)

    Time frame: From first dose of study drug to Day 22

07

Results

Posted Nov 6, 2019

Participant flow

This was a multicenter study conducted at 551 sites, including 242 sites in the United States, 142 sites in Japan, 48 sites in APAC (including Australia, New Zealand, Philippines, and South Korea), 98 sites in Europe (Belgium, Germany, Hungary, Latvia, Poland, Romania, and Spain), and 21 sites in South Africa.

Participant flow — Overall Study
MilestoneBaloxavir MarboxilPlaceboOseltamivir
Started730729725
Received study drug728728722
Intention to treat infected population388386389
Completed697695683
Not completed333442
Withdrew: Adverse event673
Withdrew: Failed inclusion/exclusion criteria003
Withdrew: Protocol deviation533
Withdrew: Lack of efficacy020
Withdrew: Withdrawal by subject131321
Withdrew: Lost to follow-up755
Withdrew: Death001
Withdrew: Miscellaneous246

Outcome measures

PrimaryTime to Improvement of Influenza Symptoms

Participants assessed the severity of 7 influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness/chills, muscle/joint pain, and fatigue) on a 4-point scale (0 = no symptoms, 1= mild, 2 = moderate, and 3 = severe). Time to improvement of symptoms was defined as the time from the start of treatment to the time when all influenza symptoms were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours: * Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline * Preexisting symptoms not worse at baseline must have maintained baseline severity * New symptoms must have alleviated, defined as a symptom score of none (0) or mild (1). Time to improvement of symptoms was analyzed using Kaplan-Meier (KM) methods; participants who did not experience improvement of symptom s were censored at the last observation.

Time frame:
From Day 1 pretreatment up to Day 14
Reported as:
Median · hours
Time to Improvement of Influenza Symptoms
hoursBaloxavir MarboxilPlaceboOseltamivir
Time to Improvement of Influenza Symptoms73.2 (67.2 to 85.1)102.3 (92.7 to 113.1)81.0 (69.4 to 91.5)
Statistical analysis
  • Baloxavir Marboxil vs Placebo · Stratified generalized Wilcoxon test · p = <0.0001 (Adjusted p-value, two-sided significance level of 0.05) · Median difference: -29.1 · 95% CI -42.8 to -14.6Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Stratified generalized Wilcoxon test · p = 0.8347 (Adjusted p-value, two-sided significance level of 0.05) · Median difference: -7.7 · 95% CI -22.7 to 7.9Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Log Rank · p = 0.0008 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Log rank test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Log Rank · p = 0.8449 (The p-value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Log rank test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
SecondaryPercentage of Participants With Positive Influenza Virus Titer at Each Time Point

Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) using tissue culture methods. Positive influenza virus titer was defined as virus titer not less than the lower limit of quantification (0.7 log₁₀ of the 50% tissue culture infective dose (TCID₅₀/mL) among those assessed for virus titer on Days 2, 3, 4, 5, 6, and 9.

Time frame:
Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Influenza Virus Titer at Each Time Point
percentage of participantsBaloxavir MarboxilPlaceboOseltamivir
Day 258.6 (53.2 to 63.9)86.9 (82.9 to 90.3)86.9 (82.9 to 90.3)
Day 331.7 (26.7 to 36.9)72.7 (67.6 to 77.4)60.0 (54.6 to 65.2)
Day 418.5 (12.2 to 26.2)50.0 (40.8 to 59.2)33.1 (24.9 to 42.1)
Day 516.0 (12.1 to 20.4)30.7 (25.7 to 36.1)20.4 (16.2 to 25.2)
Day 64.3 (1.4 to 9.9)16.0 (9.6 to 24.4)11.4 (6.0 to 19.1)
Day 92.8 (1.3 to 5.2)5.3 (3.1 to 8.3)0.9 (0.2 to 2.7)
Statistical analysis
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = <0.0001 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = <0.0001 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = <0.0001 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = <0.0001 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = <0.0001 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.0044 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = <0.0001 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.1146 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.0046 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.441 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.0929 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.0907 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
SecondaryPercentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point

Influenza virus ribonucleic acid (RNA) was quantified from nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible). The percentage of participants with detectable virus RNA (2.05 for flu A and 2.83 for flu B log₁₀ virus particles/mL) measured by reverse transcription polymerase chain reaction (RT-PCR) among those assessed on Days 2, 3, 4, 5, 6 and 9.

Time frame:
Days 2, 3, 4 (optional), 5, 6 (optional), and 9.
Reported as:
Number · percentage of participants
Percentage of Participants With Positive Influenza Virus by RT-PCR at Each Time Point
percentage of participantsBaloxavir MarboxilPlaceboOseltamivir
Day 296.0 (93.4 to 97.7)96.3 (93.8 to 97.9)96.0 (93.5 to 97.7)
Day 392.5 (89.4 to 95.0)95.4 (92.8 to 97.3)95.1 (92.4 to 97.1)
Day 486.5 (79.9 to 91.5)91.0 (85.1 to 95.1)86.4 (79.6 to 91.6)
Day 584.9 (80.8 to 88.4)88.6 (84.9 to 91.7)86.1 (82.2 to 89.5)
Day 671.8 (63.2 to 79.3)78.0 (69.7 to 85.0)71.8 (62.7 to 79.7)
Day 954.5 (49.3 to 59.8)64.9 (59.7 to 69.8)57.7 (52.3 to 62.9)
Statistical analysis
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.7383 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.9619 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.0576 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.1237 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.3071 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.9603 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.0784 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.5547 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.3087 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.9106 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.0017 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.3068 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
SecondaryChange From Baseline in Virus Titer at Each Time Point

Virus titer was quantified from nasopharyngeal swabs (or throat swabs if nasopharyngeal swabbing was not feasible) by tissue culture methods. If virus titer was less than the lower limit of quantification, the virus titer was imputed 0.7 (TCID₅₀/mL).

Time frame:
Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Reported as:
Mean · log₁₀[TCID₅₀/mL]
Change From Baseline in Virus Titer at Each Time Point
log₁₀[TCID₅₀/mL]Baloxavir MarboxilPlaceboOseltamivir
Day 2-3.36 ± 2.21-1.25 ± 2.27-1.76 ± 2.20
Day 3-3.92 ± 2.22-2.99 ± 2.55-3.26 ± 2.50
Day 4-3.99 ± 2.00-3.79 ± 2.75-3.75 ± 2.26
Day 5-4.32 ± 2.16-4.38 ± 2.31-4.41 ± 2.12
Day 6-4.07 ± 2.05-4.68 ± 2.22-4.39 ± 1.97
Day 9-4.53 ± 2.11-4.91 ± 2.08-4.78 ± 2.07
Statistical analysis
  • Baloxavir Marboxil vs Placebo · van Elteren test · p = <0.0001 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · van Elteren test · p = <0.0001 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · van Elteren test · p = <0.0001 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · van Elteren test · p = 0.0024 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · ven Elteren test · p = 0.9127 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · van Elteren test · p = 0.5361 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · van Elteren test · p = 0.5739 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · van Elteren test · p = 0.5466 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · van Elteren test · p = 0.0543 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · van Elteren test · p = 0.4677 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · van Elteren test · p = 0.0266 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · van Elteren test · p = 0.1281 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
SecondaryChange From Baseline in Virus RNA (RT-PCR) at Each Time Point

Nasopharyngeal swabs (or throat swabs, if nasopharyngeal swabbing was not feasible) were obtained for viral quantitation. Virus RNA was measured by reverse transcription polymerase chain reaction (RT-PCR).

Time frame:
Day 1 pretreatment (Baseline) and Days 2, 3, 4 (optional), 5, 6 (optional), and 9
Reported as:
Mean · log₁₀ virus particles/mL
Change From Baseline in Virus RNA (RT-PCR) at Each Time Point
log₁₀ virus particles/mLBaloxavir MarboxilPlaceboOseltamivir
Day 2-1.13 ± 1.20-0.62 ± 1.34-0.76 ± 1.18
Day 3-2.09 ± 1.45-1.57 ± 1.66-1.77 ± 1.45
Day 4-2.77 ± 1.42-2.09 ± 1.84-2.34 ± 1.63
Day 5-3.09 ± 1.58-2.77 ± 1.67-3.04 ± 1.46
Day 6-3.33 ± 1.48-3.19 ± 1.77-3.41 ± 1.38
Day 9-3.89 ± 1.51-3.78 ± 1.65-3.99 ± 1.39
Statistical analysis
  • Baloxavir Marboxil vs Placebo · van Elteren test · p = <0.0001 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · van Elteren test · p = <0.0001 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · van Elteren test · p = <0.0001 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · van Elteren test · p = 0.0015 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · van Elteren test · p = 0.0028 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · van Elteren test · p = 0.0265 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · van Elteren test · p = 0.0247 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · van Elteren test · p = 0.5298 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · van Elteren test · p = 0.9554 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · van Elteren test · p = 0.9075 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · van Elteren test · p = 0.7624 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · van Elteren test · p = 0.6156 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
SecondaryArea Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer

This endpoint was defined as AUC of change from Baseline in virus titer from Day 1 to Day 9. AUC was calculated using the trapezoidal method.

Time frame:
Day 1 to Day 9
Reported as:
Mean · log₁₀[TCID₅₀/mL]*hours
Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer
log₁₀[TCID₅₀/mL]*hoursBaloxavir MarboxilPlaceboOseltamivir
Area Under the Curve (AUC) Adjusted by Baseline in Influenza Virus Titer-727.7 ± 367.2-660.2 ± 372.3-695.5 ± 360.5
Statistical analysis
  • Baloxavir Marboxil vs Placebo · van Elteren test · p = 0.0340 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · van Elteren test · p = 0.2766 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
SecondaryArea Under the Curve (AUC) Adjusted by Baseline in Viral RNA

This endpoint was defined as AUC of change from baseline in the amount of virus RNA (RT-PCR) from Day 1 to Day 9. The AUC was calculated using the trapezoidal method.

Time frame:
Day 1 to Day 9
Reported as:
Mean · log₁₀ virus particles/mL*hours
Area Under the Curve (AUC) Adjusted by Baseline in Viral RNA
log₁₀ virus particles/mL*hoursBaloxavir MarboxilPlaceboOseltamivir
Area Under the Curve (AUC) Adjusted by Baseline in Viral RNA-490.9 ± 249.3-434.9 ± 269.3-482.2 ± 233.2
Statistical analysis
  • Baloxavir Marboxil vs Placebo · van Elteren test · p = 0.0072 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · van Elteren test · p = 0.7330 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Van Elteren test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
SecondaryTime to Cessation of Viral Shedding Determined by Virus Titer

Time to cessation of viral shedding by virus titer was defined as the time between the initiation of the study treatment and first time when the virus titer was below the limit of detection (0.7 log₁₀\[TCID₅₀/mL\]). The median and 95% confidence interval (CI) for time to cessation of viral shedding determined by virus titer was analyzed using the Kaplan-Meier (KM) method; participants whose virus titer had not reached cessation by the last observation time point were treated as censored at that time point.

Time frame:
Day 1 to Day 9
Reported as:
Median · hours
Time to Cessation of Viral Shedding Determined by Virus Titer
hoursBaloxavir MarboxilPlaceboOseltamivir
Time to Cessation of Viral Shedding Determined by Virus Titer48.0 (NA to NA)96.0 (NA to NA)96.0 (72.0 to 96.0)
Statistical analysis
  • Baloxavir Marboxil vs Placebo · Generalized Wilcoxon test · p = <0.0001 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: -48.0 · 95% CI -48.0 to -48.0Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region
  • Baloxavir Marboxil vs Oseltamivir · Generalized Wilcoxon test · p = <0.0001 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: -48.0 · 95% CI -48.0 to -24.0Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region
SecondaryTime to Cessation of Viral Shedding Determined by Virus RNA

Time to cessation of viral shedding by RT-PCR was defined as the time between the initiation of the study treatment and first time when the virus RNA was below the limit of detection measured by RT-PCR. Time to cessation of viral shedding by RT-PCR was analyzed using the KM method; participants whose virus RNA had not reached cessation by the last observation time point were treated as censored at that time point.

Time frame:
Day 1 to Day 9
Reported as:
Median · hours
Time to Cessation of Viral Shedding Determined by Virus RNA
hoursBaloxavir MarboxilPlaceboOseltamivir
Time to Cessation of Viral Shedding Determined by Virus RNA216.0 (192.0 to 240.0)240.0 (216.0 to 312.0)216.0 (216.0 to 240.0)
Statistical analysis
  • Baloxavir Marboxil vs Placebo · Generalized Wilcoxon test · p = 0.0006 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: -24.0 · 95% CI -96.0 to 0.0Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region
  • Baloxavir Marboxil vs Oseltamivir · Generalized Wilcoxon test · p = 0.2370 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: 0.0 · 95% CI -48.0 to 24.0Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region
SecondaryPercentage of Participants Whose Symptoms Were Improved at Each Time Point

Participants assessed the severity of 7 influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (0 = no symptoms, 1= mild, 2 = moderate, and 3 = severe). Improvement of symptoms was defined as all influenza symptoms alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours: * Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) judged to be worse at baseline must have improved at least 1 point from baseline severity * Preexisting symptoms judged not to be worse at baseline must have maintained baseline severity * New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1).

Time frame:
12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment
Reported as:
Number · percentage of participants
Percentage of Participants Whose Symptoms Were Improved at Each Time Point
percentage of participantsBaloxavir MarboxilPlaceboOseltamivir
12 hours9.1 (6.1 to 13.0)8.6 (5.7 to 12.3)8.1 (5.3 to 11.8)
24 hours18.8 (14.9 to 23.2)14.2 (10.8 to 18.3)19.6 (15.7 to 24.1)
36 hours33.9 (28.6 to 39.5)21.1 (16.6 to 26.1)31.0 (25.8 to 36.6)
48 hours38.0 (33.0 to 43.2)28.8 (24.2 to 33.7)39.9 (34.9 to 45.2)
72 hours56.0 (50.7 to 61.2)41.8 (36.6 to 47.1)56.0 (50.6 to 61.3)
96 hours65.9 (60.7 to 70.9)53.4 (47.9 to 58.8)61.1 (55.8 to 66.3)
120 hours72.3 (67.4 to 76.9)64.6 (59.3 to 69.7)72.4 (67.2 to 77.1)
144 hours78.1 (73.4 to 82.3)69.6 (64.4 to 74.4)77.6 (72.7 to 82.0)
168 hours80.1 (75.5 to 84.2)72.7 (67.5 to 77.5)79.6 (74.8 to 83.8)
192 hours83.6 (79.2 to 87.3)78.0 (73.2 to 82.3)85.6 (81.3 to 89.2)
216 hours85.8 (80.1 to 90.3)78.7 (71.9 to 84.6)88.2 (82.5 to 92.5)
Statistical analysis
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.7698 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.5777 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.1112 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.6483 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.0004 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.5625 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.0072 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.6234 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.0002 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.9547 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.0012 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.1860 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.0274 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.9635 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.0081 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.7425 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.0209 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.7448 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.0644 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.4931 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.0708 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.4024 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel-Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
SecondaryTime to Alleviation of Symptoms

Participants assessed the severity of seven influenza-associated symptoms (cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, and fatigue) on a 4-point scale (with 0 indicating no symptoms, 1 mild symptoms, 2 moderate symptoms, and 3 severe symptoms). Time to alleviation of symptoms was defined as the time from the start of the study treatment to the time when all seven influenza-related symptoms were assessed by the participant as absent (0) or mild (1) for at least 21.5 hours. Time to alleviation of symptoms was analyzed using Kaplan-Meier (KM) methods; participants who did not experience alleviation of symptoms were censored at the last observation time point.

Time frame:
Initiation of study treatment up to Day 14
Reported as:
Median · hours
Time to Alleviation of Symptoms
hoursBaloxavir MarboxilPlaceboOseltamivir
Time to Alleviation of Symptoms77.0 (68.4 to 88.3)102.8 (93.2 to 113.4)85.6 (71.5 to 94.8)
Statistical analysis
  • Baloxavir Marboxil vs Placebo · Generalized Wilcoxon test · p = <0.0001 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: -25.8Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Generalized Wilcoxon test · p = 0.9127 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: -8.6Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
SecondaryTime to Improvement of the Four Systemic Symptoms

Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (from 0 = no symptoms to 3 = severe symptoms). Time to improvement of the 4 systemic symptoms was defined as the time between the initiation of study treatment to the time when all 4 systemic symptoms (headache, feverishness or chills, muscle or joint pain, and fatigue) were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours: * Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline * Preexisting symptoms not worse at baseline must have maintained baseline severity * New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1). Time to improvement of the 4 systemic symptoms was analyzed using KM methods; participants who did not experience improvement of symptoms were censored at the last observation.

Time frame:
Initiation of study treatment up to Day 14
Reported as:
Median · hours
Time to Improvement of the Four Systemic Symptoms
hoursBaloxavir MarboxilPlaceboOseltamivir
Time to Improvement of the Four Systemic Symptoms51.7 (45.0 to 55.4)66.8 (60.1 to 70.0)49.4 (44.2 to 56.8)
Statistical analysis
  • Baloxavir Marboxil vs Placebo · Generalized Wilcoxon test · p = 0.0013 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: -15.1Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Generalized Wilcoxon test · p = 0.8498 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: 2.3Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
SecondaryTime to Improvement of the Three Respiratory Symptoms

Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (from 0 = no symptoms to 3 = severe symptoms). Time to improvement of the 3 respiratory symptoms was defined as the time from the start of study treatment to the time when all 3 respiratory symptoms (cough, sore throat, and nasal congestion) were alleviated, maintained, or improved, as defined below, for a duration of at least 21.5 hours: * Preexisting symptoms (cough, fatigue, or muscle/joint pain that existed prior to influenza) that were worse at baseline must have improved at least 1 point from baseline * Preexisting symptoms not worse at baseline must have maintained baseline severity * New symptoms at baseline must have alleviated, defined as a symptom score of none (0) or mild (1). Time to improvement of the 3 respiratory symptoms was analyzed using KM methods; participants who did not experience improvement of symptoms were censored at the last observation time point.

Time frame:
Initiation of study treatment up to Day 14
Reported as:
Median · hours
Time to Improvement of the Three Respiratory Symptoms
hoursBaloxavir MarboxilPlaceboOseltamivir
Time to Improvement of the Three Respiratory Symptoms63.6 (55.9 to 68.2)87.8 (76.3 to 98.9)62.1 (54.0 to 69.1)
Statistical analysis
  • Baloxavir Marboxil vs Placebo · Generalized Wilcoxon test · p = 0.0001 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: -24.1Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Generalized Wilcoxon test · p = 0.9237 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: 1.5Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
SecondaryTime to Resolution of Fever

Time to resolution of fever was defined as the time between the initiation of the study treatment and the resolution of fever. The resolution of fever was defined as the time when the participant's self-measured axillary temperature became less than 37ºC and was maintained at less than 37ºC for at least 12 hours. Time to resolution of fever was analyzed using KM methods; participants who did not experience resolution of fever by the last observation time point were censored at that time point.

Time frame:
Initiation of study treatment up to Day 14
Reported as:
Median · hours
Time to Resolution of Fever
hoursBaloxavir MarboxilPlaceboOseltamivir
Time to Resolution of Fever30.8 (28.2 to 35.4)50.7 (44.6 to 58.8)34.3 (30.0 to 38.9)
Statistical analysis
  • Baloxavir Marboxil vs Placebo · Generalized Wilcoxon test · p = <0.0001 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: -19.8 · 95% CI -28.8 to -12.5Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Generalized Wilcoxon test · p = 0.2425 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: -3.5 · 95% CI -9.1 to 2.7Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
SecondaryPercentage of Participants Reporting Normal Temperature at Each Time Point

Defined as the percentage of patrticipants whose axillary body temperature dropped to less than 37ºC after the initiation of the study treatment.

Time frame:
12, 24, 36, 48, 72, 96, 120, 144, 168, 192, and 216 hours after the initial dose of study treatment
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Normal Temperature at Each Time Point
percentage of participantsBaloxavir MarboxilPlaceboOseltamivir
12 hours29.7 (24.9 to 34.9)24.6 (20.1 to 29.5)25.9 (21.3 to 30.8)
24 hours51.1 (45.8 to 56.4)43.2 (38.1 to 48.5)54.3 (49.1 to 59.5)
36 hours68.1 (62.9 to 73.0)47.4 (42.1 to 52.8)64.1 (58.8 to 69.2)
48 hours77.4 (72.8 to 81.6)59.3 (54.1 to 64.3)76.4 (71.7 to 80.7)
72 hours84.0 (79.6 to 87.7)71.7 (66.6 to 76.5)82.6 (78.0 to 86.6)
96 hours87.5 (83.5 to 90.9)79.8 (75.0 to 84.0)85.8 (81.5 to 89.5)
120 hours86.2 (82.0 to 89.8)86.6 (82.4 to 90.1)88.4 (84.3 to 91.7)
144 hours90.0 (86.1 to 93.0)86.1 (81.9 to 89.7)87.4 (83.1 to 90.9)
168 hours87.9 (83.8 to 91.2)88.1 (84.0 to 91.5)87.7 (83.4 to 91.2)
192 hours89.0 (85.0 to 92.2)87.5 (83.3 to 91.0)90.5 (86.5 to 93.6)
216 hours89.1 (85.1 to 92.3)89.9 (85.9 to 93.1)89.6 (85.7 to 92.8)
Statistical analysis
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.1713 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.2249 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.0387 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.3915 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = <0.0001 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.2617 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = <0.0001 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.8808 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.0001 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.5923 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.0064 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.6746 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.8167 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.3773 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.1041 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.3328 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.7867 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.8640 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.6465 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.4265 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Mantel Haenszel · p = 0.6568 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Mantel Haenszel · p = 0.6102 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)Mantel Haenszel test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
SecondaryBody Temperature at Each Time Point

Participant's self-measured axillary temperature using an electronic thermometer.

Time frame:
12, 24, 36, 48, 72, 96 and 120 hours after the initial dose of study treatment
Reported as:
Least squares mean · °C
Body Temperature at Each Time Point
°CBaloxavir MarboxilPlaceboOseltamivir
12 hours37.39 ± 0.0737.53 ± 0.0737.43 ± 0.07
24 hours36.84 ± 0.0637.02 ± 0.0636.80 ± 0.06
36 hours36.58 ± 0.0636.94 ± 0.0636.62 ± 0.06
48 hours36.44 ± 0.0636.77 ± 0.0636.50 ± 0.06
72 hours36.30 ± 0.0536.46 ± 0.0536.29 ± 0.05
96 hours36.26 ± 0.0536.35 ± 0.0536.24 ± 0.05
120 hours36.26 ± 0.0536.27 ± 0.0536.21 ± 0.05
Statistical analysis
  • Baloxavir Marboxil vs Placebo · ANCOVA · p = 0.0408 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -0.14 · 95% CI -0.28 to -0.01ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.
  • Baloxavir Marboxil vs Oseltamivir · ANCOVA · p = 0.5324 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -0.04 · 95% CI -0.18 to 0.09ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.
  • Baloxavir Marboxil vs Placebo · ANCOVA · p = 0.0025 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -0.18 · 95% CI -0.30 to -0.06ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.
  • Baloxavir Marboxil vs Oseltamivir · ANCOVA · p = 0.4874 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: 0.04 · 95% CI -0.08 to 0.16ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.
  • Baloxavir Marboxil vs Placebo · ANCOVA · p = <0.0001 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -0.36 · 95% CI -0.47 to -0.24ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.
  • Baloxavir Marboxil vs Oseltamivir · ANCOVA · p = 0.5414 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -0.04 · 95% CI -0.15 to 0.08ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.
  • Baloxavir Marboxil vs Placebo · ANCOVA · p = <0.0001 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -0.33 · 95% CI -0.44 to -0.22ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.
  • Baloxavir Marboxil vs Oseltamivir · ANCOVA · p = 0.3185 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -0.06 · 95% CI -0.17 to 0.05ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.
  • Baloxavir Marboxil vs Placebo · ANCOVA · p = 0.0025 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -0.16 · 95% CI -0.26 to -0.06ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.
  • Baloxavir Marboxil vs Oseltamivir · ANCOVA · p = 0.8299 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: 0.01 · 95% CI -0.09 to 0.11ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.
  • Baloxavir Marboxil vs Placebo · ANCOVA · p = 0.0878 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -0.09 · 95% CI -0.19 to 0.01ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.
  • Baloxavir Marboxil vs Oseltamivir · ANCOVA · p = 0.7498 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: 0.02 · 95% CI -0.09 to 0.12ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.
  • Baloxavir Marboxil vs Placebo · ANCOVA · p = 0.8030 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: -0.01 · 95% CI -0.11 to 0.09ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.
  • Baloxavir Marboxil vs Oseltamivir · ANCOVA · p = 0.3577 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Ls mean difference: 0.05 · 95% CI -0.05 to 0.15ANCOVA with baseline composite symptom score, preexisting and worsened symptom, region, and body temperature at baseline as covariates.
SecondaryTime to Improvement of Individual Symptoms

Participants assessed the severity of 7 influenza-associated symptoms on a 4-point scale (0 = no symptoms to 3 = severe). Time to improvement of cough, fatigue, and muscle/joint pain was defined as the time from the start of treatment to the time when each symptom was alleviated, maintained, or improved, as defined below, for at least 21.5 hours: * Preexisting symptoms that were worse at baseline must have improved at least 1 point from baseline * Preexisting symptoms not worse at baseline must have maintained baseline severity * New symptoms must have alleviated, defined as a score of 0 (None) or 1 (Mild). Time to improvement of sore throat, headache, nasal congestion, and feverish/chills was defined as the time from the start of treatment to the time when the symptom was assessed as 0 (None) or 1 (Mild) for at least 21.5 hours. Time to improvement of symptoms was analyzed using KM methods; participants with no improvement of symptoms were censored at the last observation.

Time frame:
Initiation of study treatment up to Day 14
Reported as:
Median · hours
Time to Improvement of Individual Symptoms
hoursBaloxavir MarboxilPlaceboOseltamivir
Cough47.3 (42.8 to 52.7)70.4 (56.5 to 79.5)47.5 (43.0 to 55.4)
Sore Throat40.2 (32.4 to 46.1)46.5 (39.0 to 53.5)39.3 (30.1 to 42.8)
Headache33.4 (29.1 to 40.5)43.9 (33.6 to 46.2)31.3 (28.6 to 37.0)
Nasal Congestion45.6 (37.4 to 54.3)57.7 (48.7 to 67.8)44.0 (36.4 to 50.3)
Feverishness or Chills28.3 (24.2 to 31.8)31.9 (28.6 to 41.2)29.1 (25.2 to 30.8)
Muscle or Joint Pain37.2 (31.5 to 41.6)44.9 (42.2 to 52.0)33.2 (30.2 to 39.5)
Fatigue41.3 (35.2 to 46.1)48.8 (42.7 to 55.4)43.2 (39.3 to 47.4)
Statistical analysis
  • Baloxavir Marboxil vs Placebo · Generalized Wilcoxon test · p = 0.0009 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: -23.1Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Generalized Wilcoxon test · p = 0.4074 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: -0.2Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Generalized Wilcoxon test · p = 0.2496 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: -6.3Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Generalized Wilcoxon test · p = 0.2963 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: 0.9Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Generalized Wilcoxon test · p = 0.0390 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: -10.6Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Generalized Wilcoxon test · p = 0.7877 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: 2.0Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Generalized Wilcoxon test · p = 0.0017 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: -12.1Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Generalized Wilcoxon test · p = 0.8119 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: 1.5Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Generalized Wilcoxon test · p = 0.0070 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: -3.6Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Generalized Wilcoxon test · p = 0.9191 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: -0.7Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Generalized Wilcoxon test · p = 0.0232 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: -7.7Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Generalized Wilcoxon test · p = 0.5436 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: 4.0Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Placebo · Generalized Wilcoxon test · p = 0.0207 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: -7.5Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Generalized Wilcoxon test · p = 0.3710 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: -1.9Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
SecondaryTime to Return to Preinfluenza Health Status

Participants were asked to record their preinfluenza health status on a scale from 0 (worst possible health) to 10 (normal health \[for someone your age and condition\]), and their health status at baseline and every day after initiation of study treatment on the same scale. Return to preinfluenza health status was defined as time from the initiation of the study treatment to the first time when the health status score was equal to or higher than the preinfluenza health status score. Time to return to preinfluenza health status was analyzed using KM methods; participants with a smaller number on the scale for health status by the last observation time point were censored at that time point.

Time frame:
Baseline to Day 14
Reported as:
Median · hours
Time to Return to Preinfluenza Health Status
hoursBaloxavir MarboxilPlaceboOseltamivir
Time to Return to Preinfluenza Health Status126.4 (104.6 to 153.4)149.8 (124.7 to 175.7)126.9 (104.9 to 152.7)
Statistical analysis
  • Baloxavir Marboxil vs Placebo · Generalized Wilcoxon test · p = 0.4634 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: -23.4Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
  • Baloxavir Marboxil vs Oseltamivir · Generalized Wilcoxon test · p = 0.6386 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.) · Median difference: -0.6Peto-Prentice's generalized Wilcoxon test stratified by baseline composite symptom score, preexisting and worsened symptoms, and region.
SecondaryPercentage of Participants Requiring Systemic Antibiotics for Infections Secondary to Influenza Infection

The percentage of participants who received systemic antibiotics for any of the predefined complications (sinusitis, otitis media, bronchitis and pneumonia).

Time frame:
Day 2 to Day 22
Reported as:
Number · percentage of participants
Percentage of Participants Requiring Systemic Antibiotics for Infections Secondary to Influenza Infection
percentage of participantsBaloxavir MarboxilPlaceboOseltamivir
Percentage of Participants Requiring Systemic Antibiotics for Infections Secondary to Influenza Infection3.4 (1.8 to 5.7)7.5 (5.1 to 10.6)3.9 (2.2 to 6.3)
Statistical analysis
  • Baloxavir Marboxil vs Placebo · Fisher Exact · p = 0.0112 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)
  • Baloxavir Marboxil vs Oseltamivir · Fisher Exact · p = 0.8478 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)
SecondaryPercentage of Participants With Influenza-related Complications

Defined as the percentage of patients who experience each influenza-related complication (hospitalization, death, sinusitis, otitis media, bronchitis, and radiologically-confirmed pneumonia) as an adverse event after the initiation of study treatment.

Time frame:
Day 1 to Day 22
Reported as:
Number · percentage of participants
Percentage of Participants With Influenza-related Complications
percentage of participantsBaloxavir MarboxilPlaceboOseltamivir
Any Complications2.8 (1.4 to 5.0)10.4 (7.5 to 13.8)4.6 (2.8 to 7.2)
Death0.0 (0.0 to 0.9)0.0 (0.0 to 1.0)0.3 (0.0 to 1.4)
Hospitalization0.8 (0.2 to 2.2)1.3 (0.4 to 3.0)1.0 (0.3 to 2.6)
Sinusitis0.3 (0.0 to 1.4)2.1 (0.9 to 4.0)0.5 (0.1 to 1.8)
Otitis media0.0 (0.0 to 0.9)0.8 (0.2 to 2.3)0.3 (0.0 to 1.4)
Bronchitis1.8 (0.7 to 3.7)6.0 (3.8 to 8.8)2.3 (1.1 to 4.3)
Pneumonia0.0 (0.0 to 0.9)0.8 (0.2 to 2.3)0.5 (0.1 to 1.8)
Statistical analysis
  • Baloxavir Marboxil vs Placebo · Fisher Exact · p = <0.0001 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)
  • Baloxavir Marboxil vs Oseltamivir · Fisher Exact · p = 0.2558 (The p value was not adjusted for multiplicity, testing was conducted at the two-sided significance level of 0.05.)
SecondaryPercentage of Participants With Adverse Events (AEs)
Time frame:
From first dose of study drug to Day 22
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs)
percentage of participantsBaloxavir MarboxilPlaceboOseltamivir
Any adverse event (AE)25.129.728.0
Fatal adverse events0.00.00.1
Serious adverse events0.71.21.1
AEs leading to withdrawal of study drug0.70.70.6
Treatment-related adverse events (TRAEs)5.68.37.9
Fatal treatment-related adverse events0.00.00.0
Treatment-related serious adverse events0.00.30.3
TRAEs leading to withdrawal of study drug0.30.30.4

Adverse events

Collected over All-cause mortality data are reported from Day 1 though Day 22. Adverse events are reported from the first dose of study drug through Day 22 (i.e. treatment-emergent adverse events).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baloxavir Marboxil1/730 (0.1%)5/730 (0.7%)70/730 (9.6%)
Placebo0/727 (0%)9/727 (1.2%)92/727 (12.7%)
Oseltamivir1/721 (0.1%)8/721 (1.1%)90/721 (12.5%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventBaloxavir MarboxilPlaceboOseltamivir
CholelithiasisHepatobiliary disorders2/7300/7270/721
PneumoniaInfections and infestations1/7301/7271/721
Septic shockInfections and infestations0/7300/7271/721
Vulval abscessInfections and infestations0/7300/7271/721
Staphylococcal infectionInfections and infestations0/7300/7271/721
Diabetes mellitus inadequate controlMetabolism and nutrition disorders0/7300/7271/721
Cerebral infarctionNervous system disorders0/7300/7271/721
Arachnoid cystNervous system disorders0/7300/7271/721
Cardiac failureCardiac disorders0/7300/7271/721
HypotensionVascular disorders0/7301/7271/721
Most frequent other events
Most frequent other events
EventBaloxavir MarboxilPlaceboOseltamivir
NauseaGastrointestinal disorders20/73028/72734/721
BronchitisInfections and infestations21/73033/72730/721
DiarrhoeaGastrointestinal disorders20/73021/72723/721
SinusitisInfections and infestations14/73021/72722/721

Baseline characteristics

The Intention-to-treat Infected population includes all participants with a confirmed diagnosis of influenza virus infection who received study drug, and were enrolled at sites with Good Clinical Practice compliance. Confirmation of influenza virus infection was based on the results of reverse transcription polymerase chain reaction on Day 1.

Age, Continuous
Age, Continuous(years)Baloxavir MarboxilPlaceboOseltamivirTotal
Mean52.3 ± 16.851.9 ± 16.751.1 ± 17.051.8 ± 16.8
Age, Customized
Age, Customized(Participants)Baloxavir MarboxilPlaceboOseltamivirTotal
≥ 12 to ≤ 19 years19172258
≥ 20 to ≤ 29 years29222778
≥ 30 to ≤ 39 years425844144
≥ 40 to ≤ 49 years635575193
≥ 50 to ≤ 59 years8310183267
≥ 60 to ≤ 64 years393035104
≥ 65 to ≤ 74 years857678239
≥ 75 years28272580
Sex: Female, Male
Sex: Female, Male(Participants)Baloxavir MarboxilPlaceboOseltamivirTotal
Female195206198599
Male193180191564
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Baloxavir MarboxilPlaceboOseltamivirTotal
Hispanic or Latino625956177
Not Hispanic or Latino325327331983
Unknown or Not Reported1023
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Baloxavir MarboxilPlaceboOseltamivirTotal
American Indian or Alaska Native1236
Asian167157163487
Black or African American39302998
White178194188560
Other33612
Weight
Weight(Participants)Baloxavir MarboxilPlaceboOseltamivirTotal
< 80 kg239232233704
≥ 80 kg149154156459
Time to Treatment From Influenza Onset
Time to Treatment From Influenza Onset(Participants)Baloxavir MarboxilPlaceboOseltamivirTotal
≥ 0 to ≤ 12 hours274237106
> 12 to ≤ 24 hours151150119420
> 24 to ≤ 36 hours114120141375
> 36 to ≤ 48 hours957492261
Missing1001
Influenza Virus Subtype Based on RT-PCR Assay
Influenza Virus Subtype Based on RT-PCR Assay(Participants)Baloxavir MarboxilPlaceboOseltamivirTotal
A/H1N1pdm28173580
A/H3182185190557
B167168149484
Mixed infection45514
Other7111028

5 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Retout S, De Buck S, Jolivet S, Duval V, Cosson V. A Pharmacokinetics-Time to Alleviation of Symptoms Model to Support Extrapolation of Baloxavir Marboxil Clinical Efficacy in Different Ethnic Groups with Influenza A or B. Clin Pharmacol Ther. 2022 Aug;112(2):372-381. doi: 10.1002/cpt.2648. Epub 2022 Jun 10. PubMed 35585696 ↗
  • Ison MG, Portsmouth S, Yoshida Y, Shishido T, Mitchener M, Tsuchiya K, Uehara T, Hayden FG. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2020 Oct;20(10):1204-1214. doi: 10.1016/S1473-3099(20)30004-9. Epub 2020 Jun 8. PubMed 32526195 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Apr 2018, 15 months.

Results were first posted in Nov 2019, 1 year 6 months after primary completion. A results delay was requested in Apr 2019.

Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 15 months is above that.

Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2016
First posted
Oct 31, 2016
StartActual
Jan 11, 2017
Primary completionActual
Apr 12, 2018
CompletionActual
Apr 20, 2018
Results delay requested
Apr 10, 2019
Results first posted
Nov 6, 2019
Last update
Nov 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02949011
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Oct 31, 2016
Start date
Jan 11, 2017
Primary completion
Apr 12, 2018
Completion
Apr 20, 2018
Results posted
Nov 6, 2019
Last update
Nov 19, 2019

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
study director · Shionogi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baloxavir

Start the discussion